Consequently, BCR/Abl represents the primary target of CML therapy [3], which is based on tyrosine kinase inhibitors (TKi) targeting BCR/Abl enzymatic activity. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.